A new global clinical trial is evaluating the investigational drug FORE8394 (plixorafenib) for treatment of neuroendocrine carcinomas with BRAF V600E-mutations. The phase 2 study aims to assess the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
BRAF is a gene that makes a protein involved in cell growth. In some cancers, a mutation of this gene causes the protein to stay turned on, leading to the uncontrolled growth of cancer cells. Plixorafenib is an investigational drug that aims to inhibit this faulty signal by attaching to the mutated BRAF protein to slow or stop tumor growth. Plixorafenib is a daily oral treatment.
There are specific criteria to determine a patient’s eligibility for the study. Additional information on the study can be found at clinicaltrials.gov. Interested participants should talk to their treatment team about eligibility and determine if the study is aligned with their treatment goals.
Fore Biotherapeutics is running the trial, which will take place at 55 locations in the United States, Australia, Canada, France, Germany, Italy, the Republic of Korea, Spain, Sweden, and the United Kingdom.
For more information about the trial, contact Jessica Rine at 610-442-4517 or jessica.rine@fore.bio.